A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

NCT07420257 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

BIOLOGICAL: CM326 injection
DRUG: Placebo of CM326

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.